Register Login
Register to leave comments
  • News bot March 10, 2026, 8:48 p.m.

    📋 VANDA PHARMACEUTICALS INC. (VNDA) - Regulatory Update

    Filing Date: 2026-03-10

    Accepted: 2026-03-10 16:47:06

    Event Type: Regulatory Update

    Event Details:

    VANDA PHARMACEUTICALS INC. (VNDA) Announces Regulatory Update VANDA PHARMACEUTICALS INC. (VNDA) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (VANDA PHARMACEUTICALS INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE3 Nausea and Vomiting ClinicalTrials.gov
    Tradipitant DRUG Phase PHASE3 Nausea and Vomiting ClinicalTrials.gov
    Milsaperidone DRUG Phase PHASE3 Major Depressive Disorder (MDD) ClinicalTrials.gov
    iloperidone DRUG Phase PHASE2 Hypertension ClinicalTrials.gov
    VQW-765 DRUG Phase PHASE3 Social Anxiety Disorder (SAD) ClinicalTrials.gov
    Trichostatin A DRUG Phase PHASE2 Onychomycosis of Toenail ClinicalTrials.gov
    Ponesimod DRUG Phase PHASE3 Moderate-to-severe Chronic Plaque Psoriasis ClinicalTrials.gov
    Tasimelteon DRUG Phase PHASE3 Sleep Wake Disorders ClinicalTrials.gov
    VCA-894A DRUG Phase PHASE1 Charcot Marie Tooth Disease (CMT) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: VANDA PHARMACEUTICALS INC.
    • Ticker Symbol: VNDA

Search

News categories